Clinical Trials

Sponsor: Janssen

Sponsor Study ID: 64007957MMY3001

Study Title: A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma

NCT Number: NCT05083169

Phase: III

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Multiple Myeloma

Study Objectives:

For more information about the trial above please contact the study team:

Principal Investigator, Hamza Hashmi, at hashmih@musc.edu.
Study Coordinator, Sarah Britton, at brittosa@musc.edu, or please call +1 843-792-8856.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)